Based on the analysis of Gossamer Bio's profitability, liquidity, and operating efficiency, Gossamer Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Gossamer Bio's Net Working Capital is comparatively stable compared to the past year. Property Plant And Equipment Net is likely to gain to about 8.1 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 134 M in 2024. Key indicators impacting Gossamer Bio's financial strength include:
The financial analysis of Gossamer Bio is a critical element in measuring its lifeblood. Investors should not minimize Gossamer Bio's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(188.81 Million)
Gossamer
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Other Non Cash Items
Sale Purchase Of Stock
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Long Term Debt Total
Liabilities And Stockholders Equity
Non Current Liabilities Total
Total Liab
Total Current Assets
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Net Invested Capital
Net Working Capital
Property Plant And Equipment Net
Other Assets
Net Receivables
Common Stock Total Equity
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Capital Stock
Common Stock
Property Plant Equipment
Retained Earnings Total Equity
Capital Lease Obligations
Inventory
Non Current Liabilities Other
Short Term Debt
Net Interest Income
Interest Income
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Depreciation And Amortization
Reconciled Depreciation
Non Recurring
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Gossamer Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gossamer Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Gossamer Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.
Gossamer Bio Stock Summary
Gossamer Bio competes with Biomea Fusion, Stoke Therapeutics, Akero Therapeutics, Replimune, and Nuvectis Pharma. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Gossamer Bio's current stock value. Our valuation model uses many indicators to compare Gossamer Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gossamer Bio competition to find correlations between indicators driving Gossamer Bio's intrinsic value. More Info.
Gossamer Bio is rated below average in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . At this time, Gossamer Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gossamer Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Gossamer Bio Systematic Risk
Gossamer Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gossamer Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Gossamer Bio correlated with the market. If Beta is less than 0 Gossamer Bio generally moves in the opposite direction as compared to the market. If Gossamer Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gossamer Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gossamer Bio is generally in the same direction as the market. If Beta > 1 Gossamer Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Gossamer Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gossamer Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Gossamer Bio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Gossamer Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gossamer Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gossamer Bio based on widely used predictive technical indicators. In general, we focus on analyzing Gossamer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gossamer Bio's daily price indicators and compare them against related drivers.
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.